R&D

Pharmassist achieves another grant by “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) for expanding its R&D activities to Drug Safety/Clinical field

Pharmassist has been subsidized by the “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) Operational Program for R&D activities, regarding the development and implementation of an IT platform towards the identification, investigation and management of candidate Adverse Drug Reaction (ADR) signals, and its integration within clinical context.

Pharmassist is funded by “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) for the development of innovative technologies

Pharmassist is funded by the “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) Operational Program for the development of innovative technologies regarding the detection of predictive cancer biomarkers by liquid biopsy approach. Pharmassist’s objective is the development and commercialization of in-vitro diagnostics, establishing the liquid biopsy into clinical practice. In this project, namely CANCER blood scan, Pharmassist will collaborate with the ACTC Lab of the National and Kapodistrian University of Athens along with pronounced University Oncological Clinical Centers.

Pharmassist Ltd is now a certified organisation for carrying out R&D activities by the French Ministry of Higher Education and Research

Pharmassist is a leading full service CRO in Greece having handled with sucess numerous regulatory activities and Clinical Trials for more than 100 active local and multinational companies. As an accreditation of excellence for carrying out  R&D acctivities for the account of private companies, Pharmassist  was approved by the Ministry of Higher Education and Research.

Subscribe to RSS - R&D